Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 3 7Phase 1 3Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Completed 7Recruiting 3Terminated 2Active not recruiting 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 2Metastatic Castration-resistant Prostate Neoplasms 1

Interventions

Cyclophosphamide 119Specimen Handling 104pembrolizumab 102Magnetic Resonance Spectroscopy 96fludarabine 92Biopsy 79Injections 53Nivolumab 41venetoclax 40Bevacizumab 40Fluorouracil 38Paclitaxel 37Cisplatin 36Cetuximab 35Carboplatin 35Gemcitabine 31fludarabine phosphate 30Radiotherapy 30Oxaliplatin 30Leucovorin 28Immunotherapy, Adoptive 25Drug Therapy 25Ipilimumab 24Azacitidine 23Irinotecan 21130-nm albumin-bound paclitaxel 21tislelizumab 20Temozolomide 20Radiation 20atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × apalutamide × Clear all
NCT05818683 2026-05-08

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Recruiting
300 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

NCT06095089 2026-05-04

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Recruiting
355 enrolled
Genitourinary

Prostatic Neoplasms

NCT05413421 2025-08-11

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

ORIC Pharmaceuticals

Phase 1 Recruiting
250 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡